# 18 to 64 (Adult)

**Page range:** 43–44

```text
18 to 64 (Adult)
32 (39.0)
65 (Elderly)
32 (39.0)
Not reported
18 (22.0)
Source
Clinical Study
45 (54.9)
Non-Interventional
Study/Program
35 (42.7)
Spontaneous
1 (1.2)

12 These AEs include severity Grades as Grade 4 (n=4), Grade 3 (n=3), Grade 2 (n=1) while severity was
not reported for 4 AEs.

44
Drug Safety Report No: 1132062
Characteristic
Number of Cases (%)
Literature - Non-Interventional
Study/Program
1 (1.2)
Indication groups
Lung Cancer
60 (73.2)
Thyroid Cancer
15 (18.3)
Other malignancies
4 (4.9)
Not reported
3 (3.7)
The below Table 14 presents distribution of fatal infections by MedDRA PT.
Table 14 Distribution of Fatal AEs by MedDRA PT from Safety Database
(n=86)
Preferred Term
Frequency (%)
Pneumonia
25 (29.1)
Sepsis
19 (22.1)
COVID-19
18 (20.9)
Septic shock
6 (7.0)
COVID-19 pneumonia
4 (4.6)
Pneumonia aspiration
3 (3.5)
Urosepsis
2 (2.3)
Pneumonia cytomegaloviral, Endocarditis
bacterial, Infection, Pneumocystis jirovecii
pneumonia, Lower respiratory tract infection,
Urinary tract infection, Meningitis, Bronchitis,
Peritonitis
```